Tokyo, Japan

Shigeo Takayama


Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
2 patents (USPTO):Explore Patents

Title: **Shigeo Takayama: Innovator in Immunoassay Technology**

Introduction

Shigeo Takayama is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of immunoassay technology, particularly focusing on measuring leucine-rich alpha2 glycoprotein (LRG) in biological samples. With one patent to his name, his work is aimed at improving measurement methods in the biomedical field.

Latest Patents

Takayama holds a patent for an "Immunoassay and measurement reagent for leucine-rich alpha2 glycoprotein." The invention addresses the need for a simple and efficient method to measure LRG in biological samples within a short time frame. Through extensive research, Takayama discovered that LRG can be effectively measured using an immunoagglutination method. This involves bringing the biological sample into contact with insoluble carrier particles that carry specific anti-LRG monoclonal antibodies, enabling precise measurement.

Career Highlights

Throughout his career, Shigeo Takayama has held positions in esteemed organizations such as Sekisui Medical Co., Ltd. and the National Institutes of Biomedical Innovation, Health and Nutrition. His experience in these companies has contributed to his expertise in developing innovative measurement techniques.

Collaborations

Takayama has worked with several research institutions and companies, enhancing his inventions through collaborations. His affiliations with organizations committed to biomedical research have allowed him to refine his methodologies and expand the applications of his patent.

Conclusion

Shigeo Takayama exemplifies a dedicated inventor whose work in immunoassay technology is paving the way for advancements in medical diagnostics. His patent for measuring leucine-rich alpha2 glycoprotein underscores the importance of innovation in the health sector, promising more effective and accessible testing methods in the future.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…